>北美继发性高草酸尿症药物市场，按类型（Reloxaliase、噻嗪类利尿剂和补充剂）、药物类型（处方药和非处方药）、人群类型（儿童和成人）、最终用户（医院、专科诊所、家庭医疗保健和其他）、分销渠道（医院药房、零售药房、网上药房和其他）、国家（美国、加拿大和墨西哥）划分，行业趋势和预测至 2028 年
市场分析和洞察：北美继发性高草酸尿症药物市场
继发性高草酸尿症药物市场预计将在 2021 年至 2028 年的预测期内实现市场增长。Data Bridge Market Research 分析，在 2021 年至 2028 年的预测期内，该市场以 67.3% 的复合年增长率增长，预计到 2028 年将达到 83.4646 亿美元。由于大量摄入抗生素和饮食意识低下导致的产草酸杆菌的损失可能是继发性高草酸尿症药物市场的主要驱动力。
由于肠道问题导致吸收高浓度草酸，从而影响不同器官和组织的多因素疾病被称为继发性高草酸尿症，在极端情况下称为肠源性高草酸尿症。这种疾病与饮食和某些疾病引起的吸收不良密切相关，因为摄入草酸或草酸前体（如维生素 C）是该疾病的主要原因之一。产草酸杆菌是一种已知是继发性高草酸尿症的关键因素的细菌，它使用草酸作为完成其功能需求的关键能量元素，在疾病的发生中起着重要作用。
为了预防措施，应采取低草酸食物，但在美国、欧洲和中国等社会经济生活方式高度发达的国家，饮食习惯不正确以及缺乏饮食意识是继发性高草酸尿症的主要原因，预计这将推动继发性高草酸尿症药物市场的发展。由于目标患者数量较少导致该运营部门的收入较少，因此继发性高草酸尿症的营业收入有限，预计这将限制继发性高草酸尿症药物市场的增长。低草酸饮食很难维持，因为人们直接食用它或服用草酸的前体。市场在两个方面都提供了机会，无论是进行低草酸饮食还是另一方面，维持低草酸饮食的困难预计将成为继发性高草酸尿症药物市场增长的机会。在患者忽略药物和其他营养产品之后，肾脏替代疗法是下一步，这将显著影响药物治疗的产品使用，并导致肾脏替代疗法的需求增加，这预计将对继发性高草酸尿症药物市场的增长构成挑战。
继发性高草酸尿症药物市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息，分析了新兴收入领域、市场法规变化、产品审批、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情况，请联系我们获取分析师简报，我们的团队将帮助您创建收入影响解决方案，以实现您的预期目标。
继发性高草酸尿症药物市场范围和市场规模
继发性高草酸尿症药物市场根据类型、药物类型、人群类型、最终用户和分销渠道分为五个显著的细分市场。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
- 根据类型，继发性高草酸尿症药物市场细分为雷洛拉西酶、噻嗪类利尿剂和补充剂。2021 年，由于没有可用的靶向疗法，补充剂部分在继发性高草酸尿症药物市场中占据主导地位。然而，一些产品正在进行临床试验，预计在不久的将来会进入州际贸易。因此，疾病的管理是通过补充剂和饮食限制来完成的。钙补充剂、镁补充剂和其他补充剂是主要的治疗方法，同时还有饮食限制、液体摄入和益生菌，用于维持肠道菌群。
- 根据药物类型，继发性高草酸尿症药物市场分为处方药和非处方药。2021 年，非处方药在继发性高草酸尿症药物市场中占据主导地位，因为可用于治疗的所有产品中通常都是补充剂。成功诊断出疾病后，医生建议的治疗方法可以在柜台获得，并且由于非处方药在继发性高草酸尿症药物市场中占主导地位的原因，这些补充剂无需处方即可与常规饮食一起服用。
- 根据人口类型，继发性高草酸尿症药物市场分为儿童和成人。2021 年，成人市场在继发性高草酸尿症药物市场中占据主导地位，因为成人继发性高草酸尿症的诊断通常是针对肾结石和尿液中高草酸排泄以及尿路感染的指征进行的。儿童中肾结石的患病率并不高，与成人相比，该病的病例数相对较少。
- 根据最终用户，继发性高草酸尿症药物市场分为医院、专科诊所、家庭医疗保健和其他。2021 年，家庭医疗保健部门在继发性高草酸尿症药物市场中占据主导地位，因为目前的治疗包括补充剂和噻嗪类利尿剂。这些治疗产品由患者在家中服用，无需任何医疗专业人员的帮助和监督，因此在继发性高草酸尿症药物市场中占据主导地位。
- 根据分销渠道，继发性高草酸尿症药物市场分为医院药房、零售药房、网上药房和其他。2021 年，零售药房在继发性高草酸尿症药物市场中占据主导地位，因为这些药房的数量非常多，并且逐年增加。它们迎合了大多数患者以传统消费者购买方式购买药物的需求。此外，零售药房正致力于扩大服务范围，以提供更好的客户服务。
继发性高草酸尿症药物市场国家层面分析
对继发性高草酸尿症药物市场进行了分析，并按上述国家、类型、药物类型、人口类型、最终用户和分销渠道提供了市场规模信息。
继发性高草酸尿症药物市场报告涵盖的国家包括美国、加拿大和墨西哥。
由于诊断率和治疗率高，北美地区在继发性高草酸尿症药物市场占有大部分份额。由于人们对继发性高草酸尿症的认识不断提高，美国有望在北美市场占据主导地位。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少竞争而面临的挑战、销售渠道的影响。
维持低草酸饮食的困难和监管部门的批准支持为继发性高草酸尿症药物市场创造了新的机遇。
继发性高草酸尿症药物市场还为您提供每个国家/地区特定行业增长的详细市场分析，包括继发性高草酸尿症药物产品销售、继发性高草酸尿症药物发展的影响以及监管环境的变化及其对继发性高草酸尿症药物市场的支持。数据涵盖 2011 年至 2019 年的历史时期。
竞争格局和继发性高草酸尿症药物市场份额分析
继发性高草酸尿症药物市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对继发性高草酸尿症药物市场的关注有关。
提供继发性高草酸尿症药物市场的主要公司有葛兰素史克公司、拜耳公司、Pharmavite、Solgar Inc.、Mission Pharmacal Company、Allena Pharmaceuticals, Inc.、Celebrate Vitamins、Entring, LLC、OxThera、Renew Life Formulas, Inc.、Synlogic、TIENS、安利公司、Infinitus、Now Foods、Nature's Bounty、Renew Life Formulas, Inc. 等。DBMR 分析师了解竞争优势，并为每个竞争对手分别提供竞争分析。
全球范围内的许多公司也发起了多项产品发布和协议，这也加速了继发性高草酸尿症药物市场的发展。
例如，
- 2020 年 9 月，Allena Pharmaceuticals, Inc. 宣布与领先的生命科学投资公司 Pontifax Ventures 达成战略财务协议，总额为 2500 万美元。这笔资金将用于 Reloxaliase 和 ALLN-346 的研究，以及开发用于代谢和肾脏疾病的新型治疗药物。
- 2020 年 12 月，Synlogic 在美国化学工程师学会第三届微生物组工程国际会议上详细介绍了其肠道高草酸尿症潜在临床试验候选药物 SYNB8802。SYNB8802 目前处于肠道高草酸尿症临床试验的第 1 阶段。该公司正在介绍与该候选药物相关的开发情况，这将有助于建立公司对高草酸尿症的兴趣和方法。
市场参与者的合作、合资和其他策略正在增强公司在继发性高草酸尿症药物市场的市场，这也为组织改善其对继发性高草酸尿症药物的供应提供了好处。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS
5 REGULATORY SCENARIO OF NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET
5.1 REGULATORY FRAMEWORK FOR PROBIOTICS
5.2 REGULATORY FRAMEWORK FOR EUROPE
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 TARGETED TREATMENT FOR SECONDARY HYPEROXALURIA IS IN HIGH DEMAND
6.1.2 R&D INVESTMENT IN COMPANIES FOCUSING ON DRUG DEVELOPEMENT
6.1.3 LOW DIETARY AWARENESS IN UPPER SOCIO-ECONOMIC SOCIETY
6.1.4 INCREASED NUMBER OF CASES FOR SECONDARY HYPEROXALURIA
6.1.5 LOSS OF OXALOBACTER FORMIGENES
6.2 RESTRAINTS
6.2.1 LIMITED OPERATING REVENUE
6.2.2 HIGH COST OF TREATING SECONDARY HYPEROXALURIA
6.2.3 LIMITED SECONDARY THERAPEUTICS OPTION FOR TREATMENT
6.3 OPPORTUNITIES
6.3.1 DIFFICULTY IN MAINTAINING LOW OXALATE DIET
6.3.2 INCREASING NUMBER OF BARIATRIC SURGERY
6.3.3 REGULATORY SUPPORT FOR APPROVAL
6.3.4 RISING DISPOSABLE INCOME
6.4 CHALLENGES
6.4.1 DELAY IN DIAGNOSIS OF DISEASE LEADING TO NEED FOR RENAL REPLACEMENT
6.4.2 INCREASE FITNESS AWARENESS AMONG PEOPLE
6.4.3 INCREASE FLUID INTAKE AS A PREVENTIVE MEASURES
7 COVID-19 IMPACT ON NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET
7.1 OVERVIEW
7.2 PRICE IMPACT
7.3 IMPACT ON DEMAND
7.4 IMPACT ON SUPPLY CHAIN
7.5 STRATEGIC DECISIONS FOR MANUFACTURERS
7.6 CONCLUSION
8 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE
8.1 OVERVIEW
8.2 SUPPLEMENTS
8.2.1 OXALATE BINDING AGENTS
8.2.1.1 CALCIUM SUPPLEMENTS
8.2.1.2 MAGNESIUM SUPPLEMENTS
8.2.1.3 OTHERS
8.2.2 CITRATE SUPPLEMENTS
8.2.3 PYRIDOXINE SUPPLEMENTS
8.2.4 PROBIOTICS
8.3 THIAZIDE DIURETICS
8.4 RELOXALIASE
9 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE
9.1 OVERVIEW
9.2 OVER THE COUNTER
9.3 PRESCRIPTION
10 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE
10.1 OVERVIEW
10.2 ADULTS
10.3 CHILDREN
11 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER
11.1 OVERVIEW
11.2 HOME HEALTHCARE
11.3 HOSPITALS
11.4 SPECIALTY CLINICS
11.5 OTHERS
12 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 RETAIL PHARMACIES
12.3 HOSPITAL PHARMACIES
12.4 ONLINE PHARMACIES
12.5 OTHERS
13 NORTH AMERICA SECONDARY HYPEROXLURIA DRUG MARKET, BY GEOGRAPHY
13.1 NORTH AMERICA
13.1.1 U.S.
13.1.2 CANADA
13.1.3 MEXICO
14 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
15 COMPANY PROFILE
15.1 NESTLE
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 GLAXOSMITHKLINE PLC
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 BAYER AG
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENTS
15.4 NOW FOODS
15.4.1 COMPANY SNAPSHOT
15.4.2 COMPANY SHARE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENTS
15.5 SOLGAR INC.
15.5.1 COMPANY SNAPSHOT
15.5.2 COMPANY SHARE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENT
15.6 PHARMAVITE
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENTS
15.7 INFINITUS (CHINA)
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENTS
15.8 MISSION PHARMACAL COMPANY
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 .RECENT DEVELOPMENT
15.9 OYSTER SHELL
15.9.1 COMPANY SNAPSHOT
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENT
15.1 ALLENA PHARMACEUTICALS, INC.
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENTS
15.11 AMWAY CORP.
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENTS
15.12 CELEBRATE VITAMINS
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENTS
15.13 ENTRING, LLC
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENTS
15.14 NATURE’S BOUNTY
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 OXTHERA
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 RENEW LIFE FORMULAS, INC.
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENTS
15.17 SYNLOGIC
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENTS
15.18 TIENS
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
表格列表
LIST OF TABLES
TABLE 1 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, PIPELINE ANALYSIS
TABLE 2 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, 2019-2028 (USD MILLION)
TABLE 3 NORTH AMERICA SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 NORTH AMERICA SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA OXALATE BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA THIAZIDE DIURETICS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 NORTH AMERICA RELOXALIASE IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA OVER THE COUNTER IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA PRESCRIPTION IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA ADULTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA CHILDREN IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA HOME HEALTHCARE IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA HOSPITALS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA SPECIALTY CLINICS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA OTHERS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA RETAIL PHARMACIES IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA HOSPITAL PHARMACIES IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA ONLINE PHARMACIES IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA OTHERS PHARMACIES IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 27 NORTH AMERICA OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 32 U.S. SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 33 U.S. SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 34 U.S. OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 35 U.S. SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 36 U.S. SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 37 U.S. SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 38 U.S. SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 39 CANADA SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 40 CANADA SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 41 CANADA OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 42 CANADA SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 43 CANADA SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 44 CANADA SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 45 CANADA SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 46 MEXICO SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 47 MEXICO SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 48 MEXICO OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 49 MEXICO SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 50 MEXICO SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 51 MEXICO SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 52 MEXICO SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
图片列表
LIST OF FIGURES
FIGURE 1 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: MULTIVARIATE MODELLING
FIGURE 7 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: SEGMENTATION
FIGURE 12 LOW DIETARY AWARENESS IN UPPER SOCIO-ECONOMIC SOCIETY IS EXPECTED TO DRIVE THE NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 SUPPLEMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET IN 2021 & 2028
FIGURE 14 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET AND EUROPE IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 15 REGULATORY FRAMEWORK FOR PROBIOTICS
FIGURE 16 DRIVERS, RESTRAINT, OPPORTUNITIES AND CHALLENGE OF NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET
FIGURE 17 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, 2020
FIGURE 18 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 19 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 20 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, LIFELINE CURVE
FIGURE 21 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DRUG TYPE, 2020
FIGURE 22 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DRUGS CLASS, 2020-2028 (USD MILLION)
FIGURE 23 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DRUG TYPE, CAGR (2021-2028)
FIGURE 24 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 25 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY POPULATION TYPE, 2020
FIGURE 26 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY POPULATION TYPE, 2020-2028 (USD MILLION)
FIGURE 27 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY POPULATION TYPE, CAGR (2021-2028)
FIGURE 28 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 29 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY END USER, 2020
FIGURE 30 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 31 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY END USER, CAGR (2021-2028)
FIGURE 32 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY END USER, LIFELINE CURVE
FIGURE 33 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 34 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 35 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 36 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 37 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: SNAPSHOT (2020)
FIGURE 38 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY COUNTRY (2020)
FIGURE 39 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY COUNTRY (2021 & 2028)
FIGURE 40 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY COUNTRY (2021 & 2028)
FIGURE 41 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE (2021-2028)
FIGURE 42 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: COMPANY SHARE 2020 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
